BioNTech SE
Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- BioNTech SE (BNTX) is a biotechnology company focused on developing and commercializing immunotherapies for cancer and infectious diseases. The company offers a broad portfolio of products and services, including mRNA-based therapeutics and vaccines such as Comirnaty, its COVID-19 vaccine developed in partnership with Pfizer; individualized neoantigen-specific immunotherapies under the BioNTech's FixVac and iNeST platforms; antibody-drug conjugates; small molecule immunomodulators; and cell therapies targeting solid tumors and hematological malignancies; as well as oncology pipeline candidates like BNT327 (a PD-L1/VEGF bispecific antibody) and BNT116 (a next-generation FixVac for lung cancer). BioNTech operates primarily in the biopharmaceutical industry, serving global patient populations through clinical trials, regulatory approvals, and commercial distribution in over 30 countries across North America, Europe, Asia-Pacific, and emerging markets. Founded in 2008 and headquartered in Mainz, Germany, the company maintains subsidiaries worldwide, including in the United States, the United Kingdom, and China, with no parent company. Recent developments include the European Medicines Agency's approval in 2024 for BNT116 as the first mRNA-based lung cancer therapeutic; a multi-billion-dollar expansion of its manufacturing facilities in Rwanda and Australia announced in early 2025 to enhance global vaccine production capacity; deepened strategic alliances with Pfizer for next-generation COVID-19 vaccines and with Genentech for bispecific antibody development; and a $760 million funding round in late 2024 to advance its oncology pipeline amid robust Phase 3 trial progress.
Company News
Moderna Climbs 5% as Surprise Profit and Raised Outlook Beat Forecasts; Pfizer Dips, BioNTech Edges Higher
Axsome Therapeutics vs. BioNTech: Which Healthcare Stock Is a Better Buy for 2027?
BioNTech Q3: Bristol Myers Revenue Masks A Narrowing Oncology Bet (Rating Downgrade)
BioNTech SE (BNTX) Q3 2026 Earnings Call Transcript
BioNTech Q3 Earnings Call Highlights
BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update
Moderna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge Higher
Moderna's Rally May Have Run Out of Steam. Here's What to Watch Next
Moderna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds Steady
BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer
BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy
Moderna Tumbles 25% After Apparent Early Leak of Melanoma Vaccine Data; BioNTech Dips, Pfizer Edges Higher
BioNTech, Gilead to test drug combination in advanced breast cancer trial
BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead's TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer
BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026
BioNTech to Showcase Oncology Late-Stage Pipeline Progress and Pumitamig Novel-Novel Combination Data at ESMO 2026
Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy?
Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline
Reviewing MiMedx Group (NASDAQ:MDXG) and BioNTech (NASDAQ:BNTX)
Moderna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally; BioNTech Eases, Pfizer Stays Put